Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Q32 Bio has raised $200.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Q32 Bio's investors include RA Capital Management, Abingworth, OrbiMed, Sanofi Ventures, Agent Capital.
Q32 Bio is headquartered in Cambridge, United States.
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Q32 Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Q32 Bio — Funding & Investors." VCBacked, July 14, 2026, https://www.vcbacked.co/company/q32-bio. Accessed September 1, 2026.
VCBacked. (2026). Q32 Bio — Funding & Investors. Retrieved September 1, 2026, from https://www.vcbacked.co/company/q32-bio
{{cite web |title=Q32 Bio — Funding & Investors |url=https://www.vcbacked.co/company/q32-bio |website=VCBacked |access-date=September 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated